Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
NCT ID: NCT00888186
Last Updated: 2009-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
5 participants
INTERVENTIONAL
2008-02-29
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease
NCT03419806
Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
NCT00467597
A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612
NCT01883505
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
NCT02906488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Duodopa optimal dose
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
2. Duodopa 20% too high dose
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
3. Duodopa 10% too low dose
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
4. Duodopa 20% too low dose
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
5. Duodopa 10% too high dose
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levodopa/carbidopa
intestinal gel, for continuous daytime infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ongoing treatment with Duodopa
* Occurrence of dyskinesias, difficult to manage
* Age 30-90 years
* Hoehn \& Yahr stage 3-5 at worst
Exclusion Criteria
* Dementia
* Psychosis
* Treatment with typical neuroleptics
30 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swedish Parkinson's Disease Foundation
UNKNOWN
Swedish Society for Medical Research
OTHER
Uppsala University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Uppsala University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uppsala University Hospital
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005 Jan 25;64(2):216-23. doi: 10.1212/01.WNL.0000149637.70961.4C.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DYSK-PD-2007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.